Loading patent…
AssigneeVolant Holdings GmbH
InventorsJerome Schentag, Joseph M. Fayad
Estimating the term…
The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions.
A method of treating at least one disease state or condition selected from the group consisting of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and liver fibrosis in a human patient in need, comprising orally administering to said patient an effective amount of an ileal brake hormone releasing composition in oral dosage form comprising at least one ileal brake hormone releasing compound wherein at least 50% by weight of the ileal brake hormone releasing compound administered to said patient is released in the ileum of the patient, wherein said ileal brake hormone releasing composition is optionally coadministered with an HMG Co-A reductase inhibitor.
A pharmaceutical composition comprising an effective amount of at least one ileal brake compound in combination with an effective amount of a bioactive agent, wherein said bioactive agent is an antiviral agent selected from the group consisting of Hepsera (adefovir dipivoxil), lamivudine, entecavir, telbivudine, tenofovir, emtricitabine, clevudine, valtoricitabine, amdoxovir, pradefovir, racivir, BAM 205, nitazoxanide, UT 231-B, Bay 41-4109, EHT899, zadaxin (thymosin alpha-1) ribavirin, pegylated interferon, boceprevir, daclatasvir, asunapavir, INX-189, FV-100, NM 283, VX-950 (telaprevir), SCH 50304, TMC435, VX-500,BX-813, SCH503034, R1626, ITMN-191(R7227), R7128, PF-868554, TT033, CGH-759, GI 5005, MK-7009, SIRNA-034, MK-0608, A-837093, GS 9190, GS 9256, GS 9451, GS 5885, GS 6620, GS 9620, GS9669, ACH-1095, ACH-2928, GSK625433, TG4040 (MVA-HCV), A-831, F351, NS5A, NS4B, ANA598, A-689, GNI-104, IDX102, ADX184, ALS-2200, ALS-2158, BI 201335, BI 207127, BIT-225, BIT-8020, GL59728, GL60667, PSI-938, PSI-7977, PSI-7851, SCY-635, TLR9 Agonist, PHX1766, SP-30 or a mixture thereof.
A pharmaceutical composition comprising an effective amount of at least one ileal brake compound in combination with an effective amount of a bioactive agent, wherein said bioactive agent is an anticancer agent further in combination with an effective amount of an anticancer agent effective for treating hepatocellular cancer.
A method of treating non-alcoholic steatohepatitis (NASH) in a human patient in need, comprising orally administering to said patient an effective amount of an ileal brake hormone releasing composition in oral dosage form comprising at least one ileal brake hormone releasing compound wherein at least 50% by weight of the ileal brake hormone releasing compound administered to said patient is released in the ileum of the patient, wherein said ileal brake hormone releasing composition is optionally coadministered with an HMG Co-A reductase inhibitor.
Dependencies are inferred from the claim text.